James Anderson

James Anderson is the Executive Director of Global Health, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). There, he leads the Global Health programme of work, helping to develop policy, engage with key stakeholders and build partnerships across the public and private sectors. James’ work spans the global health sector, focusing on priority disease areas, including antimicrobial resistance (AMR), non-communicable diseases and pandemic preparedness. He also works to help address key challenges for companies, health stakeholders and patients.

Prior to joining the IFPMA in 2021, James worked in a variety of roles at GSK over a tenure of nearly two decades, most recently serving as its Head of Corporate Government Affairs.

James has been involved in establishing multiple initiatives to address AMR, including the AMR Action Fund, the Davos Declaration, the Innovative Medicines Initiative’s ‘New Drugs for Bad Bugs’ programme, the Global Antibiotic Research and Development Partnership (GARDP) and the AMR Industry Alliance. He has also served as an industry spokesperson on AMR and advisor to the O’Neill AMR Review, the UK Government-Industry Joint Task Force, the World Health Organization (WHO) and the EU Commission.

He has also chaired several industry groups. He currently chairs both the AMR Industry Alliance and the International Readiness for Preventing Infectious Viral Disease (INTREPID) Alliance on antivirals and has also served on the Board of the UK Life Science Strategy and as Vice-chair of Business at the Organisation for Economic Co-operation and Development (OECD) Healthcare Committee.